Payment overview · 2025
General Payments
$728.25
24 reported records · 14 companies
Healthcare provider profile · identity verified
Riad Robert Hajjar, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PORT HURON, MI · NPI 1538153176
Verified facts
What the public records show
CMS Open Payments records show Riad Robert Hajjar, M.D. received $728.25 in general payments during 2025 across 24 reported records.
Kerecis Limited accounted for 24.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 359 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 359 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Kerecis Limited | Unresolved — no canonical attribution shown | $177.96 | 24.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $124.74 | 17.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $87.84 | 12.1% | 4 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $67.08 | 9.2% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $57.04 | 7.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.58 | 6.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.50 | 5.3% | 2 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $25.72 | 3.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.10 | 3.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.98 | 2.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.73 | 2.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.48 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.98 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.52 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $728.25 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $177.96 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $177.96 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $124.74 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $87.84 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $58.48 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $57.04 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.58 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.58 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.50 | 2 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $25.72 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $25.10 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 359 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 71 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 142 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
359 | 65 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
63 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
71 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
142 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
359 | 65 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1112 | 236 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 906 | 118 |
| Alprazolam | Alprazolam | 673 | 109 |
| Atorvastatin Calcium | Atorvastatin Calcium | 611 | 161 |
| Pantoprazole Sodium | Pantoprazole Sodium | 524 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 511 | 145 |
| Metoprolol Tartrate | Metoprolol Tartrate | 511 | 122 |
| Furosemide | Furosemide | 487 | 117 |
| Losartan Potassium | Losartan Potassium | 436 | 109 |
| Lisinopril | Lisinopril | 430 | 110 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 418 | 82 |
| Metformin Hcl | Metformin Hcl | 404 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 379 | 107 |
| Eliquis | Apixaban | 359 | 65 |
| Gabapentin | Gabapentin | 350 | 58 |
| Omeprazole | Omeprazole | 346 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 301 | 81 |
| Trazodone Hcl | Trazodone Hcl | 294 | 57 |
| Tramadol Hcl | Tramadol Hcl | 287 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 253 | 59 |
| Carvedilol | Carvedilol | 214 | 57 |
| Allopurinol | Allopurinol | 211 | 50 |
| Potassium Chloride | Potassium Chloride | 210 | 52 |
| Simvastatin | Simvastatin | 208 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 203 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 195 | 40 |
| Montelukast Sodium | Montelukast Sodium | 182 | 43 |
| Ropinirole Hcl | Ropinirole Hcl | 147 | 34 |
| Glipizide | Glipizide | 145 | 41 |
| Ozempic | Semaglutide | 142 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 138 | 47 |
| Atenolol | Atenolol | 137 | 30 |
| Mirtazapine | Mirtazapine | 137 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 131 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 34 |
| Prednisone | Prednisone | 121 | 68 |
| Fluticasone Propionate | Fluticasone Propionate | 120 | 40 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 118 | 97 |
| Cefdinir | Cefdinir | 117 | 101 |
| Bupropion Xl | Bupropion Hcl | 114 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 103 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 103 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 100 | 19 |
| Baclofen | Baclofen | 99 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 99 | 73 |
| Jardiance | Empagliflozin | 97 | 30 |
| Famotidine | Famotidine | 95 | 23 |
| Buspirone Hcl | Buspirone Hcl | 92 | 16 |
| Ibuprofen | Ibuprofen | 91 | 28 |
| Spironolactone | Spironolactone | 84 | 24 |
| Pregabalin | Pregabalin | 83 | 14 |
| Farxiga | Dapagliflozin Propanediol | 78 | 16 |
| Xarelto | Rivaroxaban | 78 | 16 |
| Warfarin Sodium | Warfarin Sodium | 76 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 14 |
| Lorazepam | Lorazepam | 75 | suppressed |
| Ezetimibe | Ezetimibe | 74 | 21 |
| Valsartan | Valsartan | 74 | 19 |
| Mounjaro | Tirzepatide | 71 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 71 | 22 |
| Clonazepam | Clonazepam | 70 | suppressed |
| Cephalexin | Cephalexin | 68 | 45 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 67 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 67 | 20 |
| Alendronate Sodium | Alendronate Sodium | 63 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 11 |
| Nystatin | Nystatin | 62 | 33 |
| Clonidine Hcl | Clonidine Hcl | 61 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 16 |
| Cefuroxime | Cefuroxime Axetil | 59 | 45 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 12 |
| Fluconazole | Fluconazole | 58 | 38 |
| Trulicity | Dulaglutide | 58 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 57 | 17 |
| Mupirocin | Mupirocin | 57 | 30 |
| Dicyclomine Hcl | Dicyclomine Hcl | 56 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 56 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 54 | 17 |
| Novolog Flexpen | Insulin Aspart | 54 | 12 |
| Meloxicam | Meloxicam | 53 | 12 |
| Methylprednisolone | Methylprednisolone | 53 | 44 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 53 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 52 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 52 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 13 |
| Meclizine Hcl | Meclizine Hcl | 51 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 11 |
| Levofloxacin | Levofloxacin | 50 | 39 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 18 |
| Celecoxib | Celecoxib | 48 | 16 |
| Dutasteride | Dutasteride | 48 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 48 | 11 |
| Aripiprazole | Aripiprazole | 47 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 47 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 37 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 43 | 25 |
| Divalproex Sodium | Divalproex Sodium | 43 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 43 | 14 |
| Ketoconazole | Ketoconazole | 43 | suppressed |
| Loperamide | Loperamide Hcl | 42 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | suppressed |
| Diazepam | Diazepam | 41 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 41 | 15 |
| Lactulose | Lactulose | 41 | 18 |
| Lamotrigine | Lamotrigine | 41 | suppressed |
| Nitroglycerin | Nitroglycerin | 40 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 40 | 12 |
| Temazepam | Temazepam | 39 | suppressed |
| Glimepiride | Glimepiride | 38 | suppressed |
| Naproxen | Naproxen | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 20 |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Torsemide | Torsemide | 34 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 33 | suppressed |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Tradjenta | Linagliptin | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 27 |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Bumetanide | Bumetanide | 28 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | 11 |
| Methimazole | Methimazole | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 21 | 13 |
| Linzess | Linaclotide | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 18 | 16 |
| Ramipril | Ramipril | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Nystop | Nystatin | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Acetazolamide | Acetazolamide | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 12 |
| Olanzapine | Olanzapine | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Captopril | Captopril | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 11 |
| Perphenazine | Perphenazine | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $728.25 · 24 records | Kerecis Limited | AREXVY, AVYCAZ, CAPLYTA, CAPVAXIVE, DOVATO, ELIQUIS, Kerecis GraftGuide, Kerecis SurgiClose, MOUNJARO, NURTEC ODT, Ozempic, PIFELTRO, REPATHA, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, XIFAXAN | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error